HUTCHMED Announces NMPA Full Approval for ORPATHYS ® ( savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC – London Stock Exchange News Today

January 14, 2025

HUTCHMED Announces NMPA Full Approval for ORPATHYS ®( savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC – London Stock Exchange News Today – EIN Presswire

Trusted News Since 1995

A solution for worldwide experts
·
Tuesday,January 14, 2025

·.
776,742,162.Articles

·. 3 + Million Readers

Source link .

Tags
14
Advanced
announces
Approval
China
Exon
for
Full
HUTCHMED
in
Locally
MET
Metastatic
NMPA
NSCLC
or
ORPATHYS® (savolitinib)
patients
with

HUTCHMED Announces NMPA Full Approval for ORPATHYS ® ( savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC – London Stock Exchange News Today

Must Read

Pubs in England and Wales permitted to remain open later on...

Investigation released after rarely-seen shark depletes on Aussie coastline

Ashton Jeanty, Jalon Walker fit what Jaguars desire

WWE WrestleMania 41: Match Card and Where to Watch All the...

ABOUT US